[PDF] Top 20 Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
Has 10000 "Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer" found on our website. Below are the top 20 most common "Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer".
Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer
... from targeted therapies in NSCLC is of paramount ...personalized therapy in advanced NSCLC but further analysis of studies that combine chemotherapy with monoclonal antibodies targeting EGFR is ...TKI ... See full document
13
Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
... addition of TAs to chemotherapy had a tendency to improve OS in comparison with chemotherapy alone (HR 0.92, 95% CI: 0.85–1.01, P = 0.064, Figure 2) using a fixed-effects model. We then performed subgroup analysis ... See full document
7
<p>Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer</p>
... squamous cell carcinoma patients when combined with paclitaxel in a phase II ...combined therapy may provide better ...with targeted agents and/or cytotoxic chemotherapy, such as pictilisib ... See full document
18
Mechanisms of resistance to ErbB targeted cancer therapeutics
... human cancer cell lines, namely A431 squamous carcinoma cells and HN11 head and neck carcinoma cells ...EGFR- targeted TKI erlotinib and the EGFR-tar- geted monoclonal antibody cetuximab, suggesting ... See full document
5
<p>Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions</p>
... BLU-667 is another oral drug engineered to speci fi cally inhibit RET. Preclinical investigations showed that the selectivity of BLU-667 for RET is more than 100 times higher compared to other tested multi-kinase ... See full document
8
Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy
... RGDfC-SeNPs to prepare the tumor-targeting delivery sys- tem RGDfC-Se@DOX. As shown in Figure 1A, the average size of RGDfC-Se@DOX was 18 nm. The morphology of nanoparticles in TEM image presented spherical particles ... See full document
11
Postoperative survival of EGFR TKI targeted therapy in non small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
... resected non-small cell lung cancers, and 321 patients with an EGFR exon 19 deletion and 372 patients with exon 21 L858R were ...squamous cell carcinomas were ... See full document
8
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions
... annual lung cancer inci- dence counts for each ...receive non-systemic best supportive care (BSC) and do not re- ceive systemic treatment from a medical oncologist were excluded from the total ... See full document
8
Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer
... The Cancer Genome Atlas data set also displayed significantly shorter overall survival in the group with elevated PDPN mRNA ...NZ-1-IT therapy than PDPN-negative A549 cells in ... See full document
12
Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies
... which targeted therapies already exist in NSCLC (Figure ...develops lung cancer with an ALK fusion protein and treated with cri- zotinib may have their lung tumors shrink, but subsequently ... See full document
12
Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer
... and targeted therapy is an important approach in the application of targeted therapy in clinical practice, and represents an important opportunity for the development of radiotherapy ... See full document
9
MicroRNAs associated with therapy of non-small cell lung cancer
... of targeted genes in post-transcription period, miRNAs involve in biological signal channels and thus influence therapeutic ...effective therapy strategy [4, 5]. The most promising example is that NSCLC ... See full document
8
Dawn for Personalized Therapy in Non-small Cell Lung Cancer
... under circumstances where routine screening for driver genes can be done, the sequence of treatments should be decided by driver genetic mutations first, and then by histology and PS/age. EGFR mutations are tested in ... See full document
11
Profile of nintedanib in the treatment of solid tumors: the evidence to date
... in cancer treatment for several cancer ...for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic ... See full document
11
Non-small cell lung cancer therapy: safety and efficacy in the elderly
... have multiple other comorbidities, often rendering them to be high-risk surgical candidates. Case selection should occur in a multidisciplinary tumor board with dedicated thoracic surgeons, radiation oncologists, ... See full document
9
Recent advances of novel targeted therapy in non-small cell lung cancer
... In the previously described phase III TRIBUTE trial that compared chemotherapy with carboplatin/paclitaxel alone to the same regimen with the addition of erlotinib, patients with K-RAS mutations in the erlotinib group ... See full document
18
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)
... Bevacizumab (plus chemotherapy) vs. chemotherapy Five studies evaluated the cost-effectiveness of bevacizu- mab in the first-line treatment of advanced non-squamous NSCLC [15,27-30]. Four of these studies compared ... See full document
11
Salvage treatment with apatinib for advanced non-small-cell lung cancer
... interventional therapy during the duration of apatinib therapy; and 3) recurrence or metastases identified in chest, abdominal, or brain computed tomography (CT) scans and/or bone ... See full document
5
<p>Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer</p>
... Lung cancer has the highest incidence and mortality among all cancers ...from lung cancer are estimated to occur globally each year, accounting for ...1 Non-small cell ... See full document
9
Targeted therapy for localized non-small-cell lung cancer: a review
... adjuvant therapy is given, within 180 days of surgery if adjuvant chemotherapy is given, and within 270 days of surgery if adjuvant chemotherapy and postoperative radiation therapy are ... See full document
6
Related subjects